Solid Tumors After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study
Authors:
- 20 October 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (30) , 3807-3814
Abstract
Purpose: Increased risks of solid tumors after older radiotherapy strategies for testicular cancer (TC) are well established. Few population-based studies, however, focus on solid cancer risk among survivors of TC managed with nonradiotherapy approaches. We quantified the site-specific risk of solid cancers among testicular nonseminoma patients treated in the modern era of cisplatin-based chemotherapy, without radiotherapy. Patients and Methods: Standardized incidence ratios (SIRs) for solid tumors were calculated for 12,691 patients with testicular nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (1980 to 2008) and treated initially with either chemotherapy (n = 6,013) or surgery (n = 6,678) without radiotherapy. Patients accrued 116,073 person-years of follow-up. Results: Two hundred ten second solid cancers were observed. No increased risk followed surgery alone (SIR, 0.93; 95% CI, 0.76 to 1.14; n = 99 solid cancers), whereas significantly increased 40% excesses (SIR, 1.43; 95% CI, 1.18 to 1.73; n = 111 solid cancers) occurred after chemotherapy. Increased risks of solid cancers after chemotherapy were observed in most follow-up periods (median latency, 12.5 years), including more than 20 years after treatment (SIR, 1.54; 95% CI, 0.96 to 2.33); significantly increased three- to seven-fold risks occurred for cancers of the kidney (SIR, 3.37; 95% CI, 1.79 to 5.77), thyroid (SIR, 4.40; 95% CI, 2.19 to 7.88), and soft tissue (SIR, 7.49; 95% CI, 3.59 to 13.78). Conclusion: To our knowledge, this is the first large population-based series reporting significantly increased risks of solid cancers among patients with testicular nonseminoma treated in the modern era of cisplatin-based chemotherapy. Subsequent analytic studies should focus on the evaluation of dose-response relationships, types of solid cancers, latency patterns, and interactions with other possible factors, including genetic susceptibility.Keywords
This publication has 60 references indexed in Scilit:
- Second Malignant Neoplasms and Cardiovascular Disease Following RadiotherapyJNCI: Journal of the National Cancer Institute, 2012
- Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor StudyCancer Epidemiology, Biomarkers & Prevention, 2012
- Testicular Cancer Survivorship: Research Strategies and RecommendationsJNCI: Journal of the National Cancer Institute, 2010
- Testis Cancer Survivors' Health Behaviors: Comparison With Age-Matched Relative and Demographically Matched Population ControlsJournal of Clinical Oncology, 2010
- Treatment of a population based sample of men diagnosed with testicular cancer in the United StatesUrologic Oncology: Seminars and Original Investigations, 2009
- Long-term platinum retention after treatment with cisplatin and oxaliplatinBMC Clinical Pharmacology, 2008
- Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataThe Lancet Oncology, 2007
- A study of soft tissue sarcomas after childhood cancer in BritainBritish Journal of Cancer, 2007
- Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patientsEuropean Journal of Cancer, 1997
- The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapyEuropean Journal of Cancer, 1992